Infliximab for pediatric ulcerative colitis: a retrospective Italian multicenter study

Digestive and Liver Disease

Volumn 40, Issue SUPPL. 2, 2008, Pages

  Cucchiara, S ^a   Romeo, E ^a   Viola, F ^a   Cottone, M ^b   Fontana, M ^c   Lombardi, G ^d   Rutigliano, V ^e   de'Angelis, G L ^f   Federici, T ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b UNIVERSITY OF PALERMO   (Italy)

^c V BUZZI CHILDREN S HOSPITAL   (Italy)

^d Division of Pediatrics   (Italy)

^e UNIVERSITY OF BARI   (Italy)

^f UNIVERSITY OF PARMA   (Italy)

Author keywords

Infliximab; Pediatrics; Ulcerative colitis

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; DIPHENHYDRAMINE; INFLIXIMAB; MESALAZINE; METHYLPREDNISOLONE; TUMOR NECROSIS FACTOR ANTIBODY;

ADOLESCENT; ADULT; ARTHRALGIA; ARTICLE; CHILD; CHILD HEALTH CARE; CLINICAL ARTICLE; COLON RESECTION; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE COURSE; DISEASE SEVERITY; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG TREATMENT FAILURE; DYSPNEA; FEMALE; FOLLOW UP; HUMAN; HYPOTENSION; ILEOANAL ANASTOMOSIS; INFANT; ITALY; JOINT SWELLING; MALE; MEDICAL DECISION MAKING; MEDICAL RECORD REVIEW; OUTCOME ASSESSMENT; PARESTHESIA; RASH; REMISSION; SIDE EFFECT; SWEATING; TACHYCARDIA; THORAX PAIN; TREATMENT OUTCOME; ULCERATIVE COLITIS;

ADOLESCENT; ANTIBODIES, MONOCLONAL; AZATHIOPRINE; CHILD; COLITIS, ULCERATIVE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; ITALY; MALE; REMISSION INDUCTION; RETROSPECTIVE STUDIES; SALVAGE THERAPY;

EID: 45849097548     PISSN: 15908658     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1590-8658(08)60535-6     Document Type: Article

References (23)

1. Jakobovits S., Jewell D., and Travis S. Infliximab for the treatment of ulcerative colitis: outcomes in Oxford from 2000 to 2006. Aliment Pharmacol Ther 25 (2007) 1055-1060
2. Poritz L., Rwe W., Swenson B., Hollenbeak C., and Koltun W. Intravenous cyclosporine for the treatment of severe refractory ulcer-ative colitis: what is the cost?. Dis Colon Rectum 48 (2005) 1685-1690
3. Ardizzone S., and Bianchi Porro G. Biologic therapy for inflammatory bowel disease. Drugs 65 (2005) 2253-2286
4. Plevy S., Landers C., Prehn J., Carramanzana N., Deem R., Targan S., et al. A role for TNF-alpha and mucosal T helper 1 cytokines in the pathogenesis of Crohn's disease. J Immunol 159 (1997) 6276-6282
5. Guimbaud R., Bertrand V., Chauvelot-Moachon L., Quartier G., Vidon N., Giroud J., et al. Network of inflammatory cytokines and correlation with disease activity in ulcerative colitis. Am J Gastroenterol 93 (1998) 2397-2404
6. Nielsen O., Gionchetti P., Ainsworth M., Vainer B., Campieri M., Borregaard N., et al. Rectal dialysate and fecal concentrations of neutrophil gelatinase-associated lipocalin, interleukin-8, and tumor necrosis factor-alpha in ulcerative colitis. Am J Gastroenterol 94 (1999) 2923-2928
7. Watkins P., Warren B., Stephens S., Ward P., and Foulkes R. Treatment of ulcerative colitis in the cotton top tamarin using antibody to tumor necrosis factor-alpha. Gut 40 (1997) 628-633
8. Rutgeerts P., Sandborn W., Feagan B., Reinisch W., Olson A., Johanns J., et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 353 (2005) 2462-2476
9. Gisbert J., Gonzales-Lama Y., and Maté J. Systematic review: infliximab therapy in ulcerative colitis. Aliment Pharmacol Ther 25 (2006) 19-37
10. Mamula P., Markowitz J., Brown K., Hurd L., Piccoli D., and Bal-dassano R. Infliximab as a novel therapy for pediatric ulcerative colitis. J Pediatr Gastroenterol Nutr 34 (2002) 307-311
11. Russell G., and Katz A. Infliximab is effective in acute but not chronic childhood ulcerative colitis. J Pediatr Gastroenterol Nutr 39 (2004) 166-170
12. Eidelwein A., Cuffari C., Abadom V., and Oliva Hemker M. Infliximab efficacy in pediatric ulcerative colitis. Inflamm Bowel Dis 11 (2005) 213-218
13. Turner D., Otley A., Mack D., Uusoue K., Walters T., Zachos M., et al. The Development of a Valid, Reliable and Responsive Pediatric Ulcerative Colitis Activity Index (Pucai): A Prospective Multicenter Study. Gastroenterology 132 Suppl S1 (2007) A-132
14. Faubion W., Loftus E., Harmsen W., Zinsmeister A., and Sand-born W. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology 121 (2001) 255-260
15. Hyams J., Markowitz J., Lerer T., Griffiths A., Mack D., Bousvaros A., et al. The natural history of corticosteroid therapy for ulcerative colitis in children. Clin Gastroenterol Hepatol 4 (2006) 1118-1123
16. van Assche G., Vermeire S., and Rutgeerts P. Safety issues with biological therapies for inflammatory bowel disease. Curr Opin Gastroenterol 22 (2006) 370-376
17. Lees C., Heys D., Ho G., Noble C., Shand A., Mowat C., et al. A retrospective analysis of the efficacy and safety of infliximab as rescue therapy in acute severe ulcerative colitis. Aliment Pharmacol Ther 26 (2007) 411-419
18. Ferrante M., Vermeire S., Katsanos K., Noman M., Van Assche G., Schnitzler F., et al. Predictors of early response to inflixiamb in patients with ulcerative colitis. Inflamm Bowel Dis 13 (2007) 123-128
19. de Ridder L., Benninga M., Taminiau J., Hommes D., and van Deventer S. Infliximab use in children and adolescents with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 45 (2007) 3-14
20. D'Haens G. Risks and benefits of biologic therapy for inflammatory bowel diseases. Gut 56 (2007) 725-732
21. Griffiths A. Specificities of inflammatory bowel disease in childhood. Best Pract Res Clin Gastroenterol 18 (2004) 509-523
22. Polle S., and Bemelman W. Surgery insight: minimally invasive surgery for IBD. Nat Clin Pract Gastroenterol Hepatol 4 (2007) 324-335
23. Friesen C., Calabro C., Christenson K., Carpenter E., Welchert E., Daniel J., et al. Safety of infliximab treatment in pediatric patients with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 39 (2004) 265-269